Changchun High-tech (000661.SZ): The domestic production drug registration clinical trial application for injectable GenSci136 has been approved.

Wisetop Financial News APP news, Changchun High-tech (000661.SZ) announced that recently, its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical") received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The application for registration of clinical trials for the injection of GenSci136 produced domestically by Jinsai Pharmaceutical was approved. Injection of GenSci136 is a dual-target antagonist of BAFF/APRIL independently developed by Jinsai Pharmaceutical, with the Chinese registration category being Class 1 biologics for treatment, intended for the treatment of ocular myasthenia gravis (oMG).